Chronic diseases, such as cardio- and cerebrovascular diseases, chronic obstructive pulmonary diseases, and diabetes mellitus, have become important factors affecting our health as China's social economy develops. Given the trend of population aging as well as accelerated industrialization and urbanization, the prevalence of chronic diseases in China will undoubtedly rise further. The keyis prevention and control.
Type 2 diabetes (T2D) is caused by the body's inability to respond fully to insulin and is associated with various serious complications. The earlier the diagnosis, the better the outcome. Evidence suggests that metabolites such as glucose, fructose, amino acids, and lipids are typically altered in T2D patients. These metabolites are also linked to prediabetes and type 2 diabetes. Metabolomics techniques can be used to identify T2D biomarkers or to investigate how dietary changes affect metabolism in T2D patients.
Type 2 diabetes (T2D) is caused by the body's inability to respond fully to insulin and is associated with various serious complications. The earlier the diagnosis, the better the outcome. Evidence suggests that metabolites such as glucose, fructose, amino acids, and lipids are typically altered in T2D patients. These metabolites are also linked to prediabetes and type 2 diabetes. Metabolomics techniques can be used to identify T2D biomarkers or to investigate how dietary changes affect metabolism in T2D patients.
Ischemic heart disease (IHD) is the most common cardiovascular diseases (CVD) and the leading cause of CVD death worldwide. Because cardiometabolic disorders are the root of most CVD, metabolomics can be used to uncover cardiac-related metabolic changes in various stages of CVD, providing important insights into its pathogenesis and biomarker discovery. Understanding of the metabolic basis of CVD will accelerate the scientific and technological development for CVD prevention and controll.
Ischemic heart disease (IHD) is the most common cardiovascular diseases (CVD) and the leading cause of CVD death worldwide. Because cardiometabolic disorders are the root of most CVD, metabolomics can be used to uncover cardiac-related metabolic changes in various stages of CVD, providing important insights into its pathogenesis and biomarker discovery. Understanding of the metabolic basis of CVD will accelerate the scientific and technological development for CVD prevention and controll.
Chronic lung disease such as chronic obstructive pulmonary disease (COPD), asthma,and pulmonary fibrosis are complex, progressive diseases with rising morbidity and mortality rates,significantly impacting patients’ quality of life.The initial symptoms are usually mild, which impairs doctors' judgment and delays treatment. It is critical to develop rapid diagnostics to aid diagnosis, guide treatment selection, and improve prognosis management.
Chronic lung disease such as chronic obstructive pulmonary disease (COPD), asthma,and pulmonary fibrosis are complex, progressive diseases with rising morbidity and mortality rates,significantly impacting patients’ quality of life.The initial symptoms are usually mild, which impairs doctors' judgment and delays treatment. It is critical to develop rapid diagnostics to aid diagnosis, guide treatment selection, and improve prognosis management.
China has the largest population of chronic diseases of nearly 300 million patients, with an annual increase of 10 million. In China, chronic disease expenditures will increase to 5.5 trillion RMB by 2022.
People's awareness of chronic disease management has increased in recent years, making chronic disease management services a promising business opportunity in China's healthcare market. Metabolomics sheds light on the identification of biomarkers that allow for precise early diagnosis, therapy evaluation, and prognosis prediction. We will concentrate on developing a precise and innovative model based on metabolomics for the management of chronic disease at all stages.
Early Warning
Daily Interventions 
Precision Diagnostics
Are you looking to establish strategic collaboration or partnership opportunity in cancer research with an innovative and progressive research company? We are interested in collaborations with leading researchers, institutions, and facilities with proven track records. Contact us or leave your message below.
Service hotline
0755-26921231Address
